Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Roy Carambula"'
Publikováno v:
Journal of clinicalcellular immunology. 10(1)
This review examines some of the reasons why we don’t have a vaccine against autoimmune diseases and highlights the progress that has been made. Many autoimmune diseases, such as rheumatoid arthritis (RA), multiple sclerosis (MS) and type 1 diabete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e913d78b7a34466679cf2bac91bf8e63
https://pubmed.ncbi.nlm.nih.gov/31328022
https://pubmed.ncbi.nlm.nih.gov/31328022
Autor:
Daniel H Zimmerman, Katalin Mikecz, Kenneth S Rosenthal, Adrienn Markovics, Roy Carambula, Jason Ciemielewski, Tibor Glant
Publikováno v:
The Journal of Immunology. 202:133.4-133.4
Background Development of a therapeutic vaccine for rheumatoid arthritis (RA) requires modulating antigen specific inflammatory T cell responses that drive disease. RA can be initiated and driven by responses to multiple antigens but peptide vaccines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed48fd0fd79d1b59efd86c2ef3d6362c
https://doi.org/10.4049/jimmunol.202.supp.133.4
https://doi.org/10.4049/jimmunol.202.supp.133.4
Autor:
Daniel H Zimmerman, Kenneth Rosenthal, Roy Carambula, Steve Cress, Adrienn Markovics, Tibor Glant, Katalin Mikecz
Publikováno v:
The Journal of Immunology. 198:224.14-224.14
Background Pro-inflammatory T helper (Th)17 or Th1 cell responses (IL17, IFNγ, TNFα) drive autoimmune pathology in rheumatoid arthritis (RA) at the expense of anti-inflammatory/regulatory (IL4, IL10, TGFβ) T cell responses. Ligand Epitope Antigen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c50c5dc1a50c62252785fd34ecee0f91
https://doi.org/10.4049/jimmunol.198.supp.224.14
https://doi.org/10.4049/jimmunol.198.supp.224.14
Publikováno v:
The Journal of Immunology. 190:67.6-67.6
Introduction. A major therapeutic goal in autoimmune inflammatory diseases such as rheumatoid arthritis (RA) is to suppress responses against (auto)antigens present in the target organs. Antigen-specific therapies such as the Ligand Epitope Antigen P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e2e6f0be48c8ad6eccf2b947389be451
https://doi.org/10.4049/jimmunol.190.supp.67.6
https://doi.org/10.4049/jimmunol.190.supp.67.6